[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640771":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":44,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adebrelimab and nab-paclitaxel plus carboplatin followed by radiotherapy","EXPERIMENTAL","Patients would receive Adebrelimab (IV 1200mg d1) and nab-paclitaxel (IV 220 mg\u002Fm²d1) plus carboplatin (AUC = 5, d1) for two 21-day cycles, followed by one week off for radiotherapy (2.5 ⨉12 Gy). After radiotherapy, another cycle of Adebrelimab (IV 1200mg d1) would be given. 4 to 6 weeks after completing the neoadjuvant therapy, patients would undergo esophagectomy.",[13],"Drug: • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","• Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Baisheng Chen, M.D, PhD","CONTACT","+86-13560471611","Pason06213367@163.com",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":19,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Guangzhou","Guangdong","China","CN",{"type":34,"coordinates":35},"Point",[36,37],113.25,23.11667,{"lat":37,"lon":36},[40],{"name":41,"role":23,"phone":24,"phoneExt":19,"email":25},"Baisheng Chen Chen",{"type":43,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[45],{"name":46,"class":47},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY","100640771","phase-2-adebrelimab-combined-with-neoadjuvant-chemoradiotherapy-for-esophageal-squamous-cell-carcinoma-100640771",false,"NCT07595770","Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma","A Study on the Safety and Efficacy of Adalimumab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma","ANCRE","Inclusion Criteria:\n\n* \\- 1. Provided informed consent and sign the informed consent form;\n* 2\\. Male or female, Aged 18-75 years (counted on the date of signing informed consent);\n* 3\\. Pathological confirmed ESCC;\n* 4\\. Patients assessed by thoracic oncologists as resectable without distant metastasis\n* 5\\. Patients evaluate with clinical staging of T1-4aN1-3M0 or T3-4aN0M0(AJCC 9.0) based on imaging and pathological examination results;\n* 6\\. Have at least one assessable lesion according to the RECIST V1.1\n* 7\\. ECOG-PS score: 0-1;\n* 8\\. Patients with normal function of organs such as heart, brain, lungs, and kidneys who can tolerate surgery;\n* 9\\. With a life expectancy of ≥ 6 weeks;\n* 10\\. Adequate major organ function without severe hematologic, cardiac, pulmonary, hepatic, renal, or bone marrow dysfunction, and no immunodeficiency disease;\n\nExclusion Criteria:\n\n* 1\\. Patients who have received or are currently receiving chemotherapy, radiotherapy, immunotherapy, or targeted therapy\n* 2\\. Patients with distant metastasis or inability to undergo resection after evaluation by thoracic surgeons\n* 3\\. Simultaneously developing tumors in other parts of the body\n* 4\\. Severe impairment of heart, liver, and kidney function (heart function grade 3-4, ALT and\u002For AST exceeding the upper limit of normal by more than 1.5 times, Cr (serum creatinine) exceeding the upper limit of normal by more than 1.5 times)\n* 5\\. Patients with a history of autoimmune diseases who were receiving immunosuppressive therapy prior to enrollment, with immunosuppressive doses\\>10 mg\u002Fday or oral prednisone for more than 2 weeks\n* 6\\. Severe allergy to immune preparations\n* 7\\. Abnormal coagulation function: (PT\\>16s, APTT\\>53s, TT\\>21s, Fib\\\u003C1.5 g\u002FL), bleeding tendency or during thrombolytic or anticoagulant therapy\n* 8\\. Pregnancy or lactation period\n* 9\\. Other situations as judged by investigators not suitable for inclusion.;","ALL","18 Years","75 Years",{"count":60,"type":61},37,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.",[67],"Esophageal Squamous Cell Carcinoma (ESCC)",[69,70,71,72],"chemotherapy","radiotherapy","immune checkpoint inhibitors","adebrelimab","2026-05-13",{"date":75,"type":76},"2026-05-19","ACTUAL",{"date":78,"type":61},"2026-05-22",{"date":80,"type":61},"2029-10-01",{"name":5,"class":6},1]